Tag archive for ‘Amgen’
Cytokinetics; Amgen and Servier Announce Decision to Move Omecamtiv Mecarbil into Phase 3 (CYTK, Buy, $12.07)
Amgen issued a press release today in which it announced that Servier had decided to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, Russia and certain other territories. The companies announced that the Phase 3 program of omecamtiv mecarbil will move forward in collaboration with Cytokinetics. I think that the gating […]
Cytokinetics: Amgen’s R&D Chief Expresses Great Optimism About Omecamtiv Mecarbil for Treating Congestive Heart Failure (CYTK, Buy, $6.53)
Purpose of This Report I have written frequently about omecamtiv mecarbil, Cytokinetics’ extremely promising new drug for congestive heart failure (CHF). I believe that it has the potential to be a therapeutic breakthrough for CHF which can significantly reduce mortality and morbidity. I see it as an add-on therapy to current standard of care drugs […]
Cytokinetics: Presentation at Heart Failure Society Suggests Myocardial Infarctions Are Not Likely Associated with Omecamtiv Mecarbil (CYTK, $7.61)
Investment Background Cytokinetics and Amgen first presented data from the ATOMIC HF trial at the European Society of Cardiology Congress (ESC) on September 2, 2013. This was a 48 hour dose ranging study in patients who were hospitalized with heart failure. The objective of the study was to determine pharmacokinetic (describes how the body affects […]
Cytokinetics: Clinical Investigators’ Take on ATOMIC-AHF Trial Results (CYTK, $8.01)
Introduction Cytokinetics issued a press release on the results of the phase II trial of ATOMIC-AHF and then held a conference call on September 3. Before the results were discussed in the conference call, news wires reported that the trial had missed its primary endpoint and this caused an immediate sharp sell-off in the stock. […]
Cytokinetics: A Preview of Key Upcoming Clinical Trial Results (CYTK, $10.17)
Introduction This report is an update on my thinking on Cytokinetics. It should be read in conjunction with earlier reports, especially my initiation report of March 15, Cytokinetics: Critical Phase IIB Data is Upcoming in 2013 for Omecamtiv Mecarbil and Tirasemtiv (CYTK, $6.30). In that report, I first recommended purchase and I continue to do […]
Cytokinetics (CYTK, $1.40) Receives a Vote of Confidence from Amgen
Cytokinetics (CYTK) has announced an expansion of the partnering agreement with Amgen (AMGN) for omecamtiv mecarbil, the Company’s lead product which is being developed for congestive heart failure. In the original agreement, rights to omecamtiv in Japan were not included. The expansion gives Amgen rights in Japan as well. Cytokinetics will receive $25 million which […]